Incidence rates increased only for cancers and melanoma of the prostate, kidney, and esophagus. When a process referred to as delay adjustment is certainly taken into account, a few of these trends modification . For the first time, lung malignancy incidence rates among females are on the decline. Incidence prices decreased for five extra cancers from the best 15 in ladies . Only breasts, thyroid, bladder, and kidney melanoma and cancer prices are rising among ladies. This year’s statement highlights trends in cancer survival by evaluating five-year survival rates of cancer patients diagnosed in two schedules: 1975-1979 and 1995-2000. Between those schedules, survival substantially improved for most of the very best 15 cancers in both women and men, and the top ten sites in children. For men, large gains in cancer survival rates were observed in cancers of the prostate, kidney and colon, and non-Hodgkin lymphoma, melanoma, and leukemia.BerGenBio provides been offered this award in reputation of its market-leading development and entrepreneurial abilities in the Nordic existence technology community. Related StoriesInvestment in radiotherapy solutions could save lives, increase overall economy in developing countriesFDA approves LONSURF for treatment of sufferers with metastatic colorectal cancerMajority of tumor patients lack usage of safe, affordable medical careOn news of the award, Richard Godfrey, CEO of BerGenBio, commented: That is an exciting period for all of us at BerGenBio.